Stock Analysis
Dezhan Healthcare First Quarter 2024 Earnings: CN¥0.008 loss per share (vs CN¥0.001 profit in 1Q 2023)
Dezhan Healthcare (SZSE:000813) First Quarter 2024 Results
Key Financial Results
- Revenue: CN¥101.3m (down 25% from 1Q 2023).
- Net loss: CN¥16.8m (down from CN¥1.86m profit in 1Q 2023).
- CN¥0.008 loss per share (down from CN¥0.001 profit in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Dezhan Healthcare shares are down 2.6% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Dezhan Healthcare you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Dezhan Healthcare is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:000813
Dezhan Healthcare
Engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China.
Adequate balance sheet with questionable track record.